F Lehmann-Horn, W Klingler… - Anesthesiology, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Lehmann-Horn, Frank MD, Ph.D.; ...
[PDF] from bmrservice.comC Giulivi, C Ross-Inta, A Omanska-Klusek… - Journal of Biological …, 2011 - ASBMB Malignant hyperthermia (MH) and central core disease in humans have been associated with mutations in the skeletal ryanodine receptor (RyR1). Heterozygous mice expressing the human MH/central core disease RyR1 R163C mutation exhibit MH when exposed to halothane ... Related articles - All 5 versions
H Rosenberg… - European Journal of Human Genetics, 2011 - nature.com The clinical specificity can be dependent on variable factors, such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case. ... Life-time risk to develop the disease when patient is exposed to 'trigger' ... Related articles - All 3 versions
W Feng, GC Barrientos, G Cherednichenko… - Molecular …, 2011 - ASPET Mutations in ryanodine receptor type 1 (RyR1) confer malignant hyperthermia susceptibility. How inherent impairments in Ca 2+ channel regulation affect skeletal muscle function in myotubes and adult fibers under basal (nontriggering) conditions are not understood. Myotubes, ... Related articles
N Kraeva, S Riazi, J Loke, W Frodis… - Canadian Journal of …, 2011 - Springer Ryanodine receptor type 1 gene mutations found in the Canadian ... Observation de mutations génétiques des récepteurs de la ... Natasha Kraeva, PhD • Sheila Riazi, MD • Julian Loke, MBBS • Wanda Frodis, BSc • Mary Lou Crossan, BA • Kevin Nolan, MD • Alexander Kraev, PhD • ... Cited by 1 - Related articles - All 4 versions